A phase II study of carboplatin plus gemcitabine in advanced non-small- cell lung cancer (NSCLC): A hoosier oncology group study

Elizabeth W. Ng, Alan B. Sandler, Leslie Robinson, Lawrence Einhorn

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The purpose of this study was to evaluate the toxicity and determine the response rate, duration of remission, and survival using gemcitabine plus carboplatin in non-small cell lung cancer (NSCLC). This was a phase II study of gemcitabine and carboplatin in chemotherapy-naive patients with advanced NSCLC and Karnofsky Performance Status of at least 80. Gemcitabine was administered intravenously at 1,000 mg/m2 weekly for 3 weeks followed by 1 week rest. Carboplatin was administered immediately after gemcitabine at an area under the curve (AUC) of 5 given intravenously on day 1 of an every-4- week cycle. Seven patients were entered in the study and five were evaluable for toxicity. The median age of patients was 68 years (range, 52-72). The protocol was prematurely terminated because of severe and unexpected hematologic toxicity. Grade 3-4 thrombocytopenia was observed in four of the first five patients. These toxicities were all observed with the first course of chemotherapy. There were no objective responses seen. Median survival time was 130 days. Carboplatin plus gemcitabine was a logical combination. However, because of the severe thrombocytopenia associated with this regimen, we do not recommend this two-drug combination in the dose and schedule used in this study.

Original languageEnglish
Pages (from-to)550-553
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number6
DOIs
StatePublished - Dec 1999

Fingerprint

gemcitabine
Carboplatin
Non-Small Cell Lung Carcinoma
Karnofsky Performance Status
Drug Therapy
Survival
Drug Combinations
Thrombocytopenia
Area Under Curve
Appointments and Schedules

Keywords

  • Carboplatin
  • Gemcitabine
  • Non-small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II study of carboplatin plus gemcitabine in advanced non-small- cell lung cancer (NSCLC) : A hoosier oncology group study. / Ng, Elizabeth W.; Sandler, Alan B.; Robinson, Leslie; Einhorn, Lawrence.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 22, No. 6, 12.1999, p. 550-553.

Research output: Contribution to journalArticle

@article{ccb7956831494fdc9177fbf7082f90d0,
title = "A phase II study of carboplatin plus gemcitabine in advanced non-small- cell lung cancer (NSCLC): A hoosier oncology group study",
abstract = "The purpose of this study was to evaluate the toxicity and determine the response rate, duration of remission, and survival using gemcitabine plus carboplatin in non-small cell lung cancer (NSCLC). This was a phase II study of gemcitabine and carboplatin in chemotherapy-naive patients with advanced NSCLC and Karnofsky Performance Status of at least 80. Gemcitabine was administered intravenously at 1,000 mg/m2 weekly for 3 weeks followed by 1 week rest. Carboplatin was administered immediately after gemcitabine at an area under the curve (AUC) of 5 given intravenously on day 1 of an every-4- week cycle. Seven patients were entered in the study and five were evaluable for toxicity. The median age of patients was 68 years (range, 52-72). The protocol was prematurely terminated because of severe and unexpected hematologic toxicity. Grade 3-4 thrombocytopenia was observed in four of the first five patients. These toxicities were all observed with the first course of chemotherapy. There were no objective responses seen. Median survival time was 130 days. Carboplatin plus gemcitabine was a logical combination. However, because of the severe thrombocytopenia associated with this regimen, we do not recommend this two-drug combination in the dose and schedule used in this study.",
keywords = "Carboplatin, Gemcitabine, Non-small-cell lung cancer",
author = "Ng, {Elizabeth W.} and Sandler, {Alan B.} and Leslie Robinson and Lawrence Einhorn",
year = "1999",
month = "12",
doi = "10.1097/00000421-199912000-00003",
language = "English",
volume = "22",
pages = "550--553",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A phase II study of carboplatin plus gemcitabine in advanced non-small- cell lung cancer (NSCLC)

T2 - A hoosier oncology group study

AU - Ng, Elizabeth W.

AU - Sandler, Alan B.

AU - Robinson, Leslie

AU - Einhorn, Lawrence

PY - 1999/12

Y1 - 1999/12

N2 - The purpose of this study was to evaluate the toxicity and determine the response rate, duration of remission, and survival using gemcitabine plus carboplatin in non-small cell lung cancer (NSCLC). This was a phase II study of gemcitabine and carboplatin in chemotherapy-naive patients with advanced NSCLC and Karnofsky Performance Status of at least 80. Gemcitabine was administered intravenously at 1,000 mg/m2 weekly for 3 weeks followed by 1 week rest. Carboplatin was administered immediately after gemcitabine at an area under the curve (AUC) of 5 given intravenously on day 1 of an every-4- week cycle. Seven patients were entered in the study and five were evaluable for toxicity. The median age of patients was 68 years (range, 52-72). The protocol was prematurely terminated because of severe and unexpected hematologic toxicity. Grade 3-4 thrombocytopenia was observed in four of the first five patients. These toxicities were all observed with the first course of chemotherapy. There were no objective responses seen. Median survival time was 130 days. Carboplatin plus gemcitabine was a logical combination. However, because of the severe thrombocytopenia associated with this regimen, we do not recommend this two-drug combination in the dose and schedule used in this study.

AB - The purpose of this study was to evaluate the toxicity and determine the response rate, duration of remission, and survival using gemcitabine plus carboplatin in non-small cell lung cancer (NSCLC). This was a phase II study of gemcitabine and carboplatin in chemotherapy-naive patients with advanced NSCLC and Karnofsky Performance Status of at least 80. Gemcitabine was administered intravenously at 1,000 mg/m2 weekly for 3 weeks followed by 1 week rest. Carboplatin was administered immediately after gemcitabine at an area under the curve (AUC) of 5 given intravenously on day 1 of an every-4- week cycle. Seven patients were entered in the study and five were evaluable for toxicity. The median age of patients was 68 years (range, 52-72). The protocol was prematurely terminated because of severe and unexpected hematologic toxicity. Grade 3-4 thrombocytopenia was observed in four of the first five patients. These toxicities were all observed with the first course of chemotherapy. There were no objective responses seen. Median survival time was 130 days. Carboplatin plus gemcitabine was a logical combination. However, because of the severe thrombocytopenia associated with this regimen, we do not recommend this two-drug combination in the dose and schedule used in this study.

KW - Carboplatin

KW - Gemcitabine

KW - Non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0033512165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033512165&partnerID=8YFLogxK

U2 - 10.1097/00000421-199912000-00003

DO - 10.1097/00000421-199912000-00003

M3 - Article

C2 - 10597737

AN - SCOPUS:0033512165

VL - 22

SP - 550

EP - 553

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -